The Sareum Holdings Plc (LON: SAR) share price edged 3.89% higher after revealing that it had dosed the first patients in the Phase 1a clinical trial for its lead programme SDC-1801, which is a dual TYK2/JAK1 kinase inhibitor that could become a psoriasis treatment.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
Sareum’s SDC-1801 drug candidate targets autoimmune diseases such as psoriasis, which affects the skin. The dosing for the Phase 1a clinical trial has started at a specialist clinical division in Melbourne, Australia.
Top Broker Recommendation
- eToro Top stock trading platform with 0% commission – Read our Review
- Tickmill Regulated by the FCA – Read our Review
- Admirals (Admiral Markets) More than 4500 stocks & ETFs available – Read our Review
- Spreadex Spreadex has been around for a long time – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
The Phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral formulation of SDC-1801 in healthy subjects. The trial will be a randomised, placebo-controlled trial with single and multiple ascending oral dosage studies.
Sareum expects to receive the final safety data in the first half of 2024 and will proceed with the Phase 1b clinical study if the safety data meets expectations.
Sareum’s CEO, Dr Tim Mitchell, commented: “We are delighted to begin dosing the first subjects in our Phase 1a trial of SDC-1801. Dual TYK2 and JAK1 inhibition offer significant potential benefits for immune health, and we believe by targeting both these pathways, SDC-1801 could have the potential for superior efficacy in autoimmune disease compared to agents that block just one of the two kinases. Dosing of the first subjects in this trial is an important first step to establishing the safety and tolerability profile of SDC-1801, and we look forward to watching the trial progress.”
Sareum got approval to run the clinical trial from Australia’s Human Research Ethics Committee (HREC) and was acknowledged by Australia's medicines regulator, the Therapeutic Goods Administration (TGA), after filing a Clinical Trial Notification (CTN) scheme in early May.
The company did not waste any time moving forward with the clinical trial since it started dosing study participants barely a month later.
*This is not investment advice.
Sareum share price.
The Sareum share price edged 3.89% higher to trade at 140.25p, from Monday’s closing price of 135.00p.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.